Investigating the interaction between aryl hydrocarbon receptor and methotrexate: implications for treatment resistance in rheumatoid arthritis patients
Pharmacological Reports · 2026-08 · 78 (4) · 1217-1235
DOI: 10.1007/s43440-026-00875-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Reports, online erschienen am 22.06.2026. Verfasst von Anna Wajda und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warszawa, Poland. annawajda2046@gmail.com. Hauptthemen laut MEDLINE: Methotrexate, Arthritis, Rheumatoid, Receptors, Aryl Hydrocarbon, Antirheumatic Agents. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Polish Ministry of Science and Higher Education through statutory funding for the National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Po…, Polish Ministry of Science and Higher Education through statutory funding for the National Medicines Institute.
Abstract (Originalsprache)
Background
The aryl hydrocarbon receptor (AHR) plays a key role in immune regulation and drug metabolism, potentially influencing methotrexate (MTX) treatment outcomes in patients with rheumatoid arthritis (RA). This exploratory study investigated the relationship between AHR activity and MTX responsiveness, and examined whether combination therapy with tocilizumab (TCZ), an interleukin (IL)-6 receptor inhibitor, could influence MTX resistance and treatment response.
Methods
We employed in silico docking to assess MTX binding to the AHR Per-Arnt-Sim (PAS)-B domain. Ex vivo and in vitro models using peripheral blood mononuclear cells (PBMCs) from RA patients and healthy donors were also used. Flow cytometry was used to analyze AHR expression across immune cell subtypes. Additionally, HepG2 cells served as a pharmacological model to study the interaction of MTX and TCZ with AHR and the expression of drug transporter genes.
Results
AHR expression was significantly higher in monocytes from good responders to MTX than in those from poor responders and MTX-intolerant patients, suggesting that monocytes were the PBMC subset most strongly associated with AHR-related patterns of MTX response. In silico analysis supported the binding of MTX to the PAS-B domain of AHR. The in vitro model confirmed that monocytes were the most responsive subset in the context of AHR-related changes. Treatment with TCZ tended to reduce the proportion of AHR-positive monocytes, whereas co-treatment with MTX shifted AHR toward a pattern comparable to that in good responders or under control conditions.
Conclusions
Our findings underscore the complexity of MTX pharmacodynamics and highlight AHR as a potential biomarker for predicting treatment response in RA patients. The combination of MTX and TCZ modulated AHR activity and could inform personalized therapeutic strategies, especially in patients exhibiting MTX resistance or intolerance. While preliminary, this multi-layered investigation—combining patient samples, 3D cultures, and molecular docking—supports further research into AHR-modulating therapies in RA. Clinical trial number Not applicable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warszawa, Poland. annawajda2046@gmail.com.
- Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warszawa, Poland.
- Department of Pathophysiology and Immunology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warszawa, Poland.
- National Medicines Institute, Warszawa, Poland.
- Paediatric Regional Centre for Digital Medicine, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, Warsaw, 04-730, Poland.
- Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warszawa, Poland.
Förderung
- Polish Ministry of Science and Higher Education through statutory funding for the National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Po…
- Polish Ministry of Science and Higher Education through statutory funding for the National Medicines Institute
Zitieren
APA
Wajda, A., Filipowicz, G., Kaliberda, Y., Stypińska, B., Kmiołek, T., Kuca-Warnawin, E., Jarończyk, M., Matusiewicz, A., Jaszczyk, B., Stasiek, M., Felis-Giemza, A., Bazała, K., Ejma-Multański, A., Bogucka, D., Modzelewska, E., Olesińska, M., & Paradowska-Gorycka, A. (2026). Investigating the interaction between aryl hydrocarbon receptor and methotrexate: implications for treatment resistance in rheumatoid arthritis patients. Pharmacological Reports, 78(4), 1217-1235. https://doi.org/10.1007/s43440-026-00875-1
Vancouver
Wajda A, Filipowicz G, Kaliberda Y, Stypińska B, Kmiołek T, Kuca-Warnawin E, et al. Investigating the interaction between aryl hydrocarbon receptor and methotrexate: implications for treatment resistance in rheumatoid arthritis patients. Pharmacological Reports. 2026;78(4):1217-1235. doi:10.1007/s43440-026-00875-1
BibTeX
@article{Wajda2026,
author = {Wajda, Anna and Filipowicz, Gabriela and Kaliberda, Yana and Stypińska, Barbara and Kmiołek, Tomasz and Kuca-Warnawin, Ewa and Jarończyk, Małgorzata and Matusiewicz, Agata and Jaszczyk, Bożena and Stasiek, Małgorzata and Felis-Giemza, Anna and Bazała, Katarzyna and Ejma-Multański, Adam and Bogucka, Diana and Modzelewska, Ewa and Olesińska, Marzena and Paradowska-Gorycka, Agnieszka},
title = {Investigating the interaction between aryl hydrocarbon receptor and methotrexate: implications for treatment resistance in rheumatoid arthritis patients},
journal = {Pharmacological Reports},
year = {2026},
volume = {78},
number = {4},
pages = {1217--1235},
doi = {10.1007/s43440-026-00875-1}
}
EUVIMED